Ocrevus

This page shows the latest Ocrevus news and features for those working in and with pharma, biotech and healthcare.

Roche’s Ocrevus boasts positive long-term data in MS

Following two years of using Ocrevus twice-yearly, 75% of relapsing-remitting multiple sclerosis (RRMS) patients had no evidence of disease activity. ... Ocrevus. Patients treated with Ocrevus also experienced an improvement in the majority of their

Latest news

Novartis wins FDA approval for relapsing MS drug Kesimpta

However, the drug will have fierce competition in the market, from rivals such as Roche’s Ocrevus (ocrelizumab) and Sanofi’s Aubagio, despite touting superior efficacy data over the latter. ... Both Kesimpta and Ocrevus selectively target the immune
Roche’s Soliris rival Enspryng bags FDA approval

The FDA approval of Enspryng, the first subcutaneous NMOSD treatment using novel recycling antibody technology, builds upon the work we’ve done in multiple sclerosis with Ocrevus to develop
Novartis builds its case for novel MS treatment ofatumumab

The MS market has long been dominated by Roche’s blockbuster drug Ocrevus (ocrelizumab), which is used in both relapsing forms of MS and primary progressive MS, although it is facing
Roche cites COVID-19 and biosimilars in Q2 decline

Although sales of Roche's newer drugs climbed by 37%, including haemophilia A treatment Hemlibra (emicizumab), multiple sclerosis therapy Ocrevus (ocrelizumab) and PD-1 inhibitor Tecentriq (atezolizumab), this was unable to ... In fact, uptake of both
J&J aims for US approval of MS drug ponesimod

A range of blockbuster therapies are already available for MS, including Biogen’s Tecfidera (dimethyl glutamate) and new injectables like Roche’s Ocrevus (ocrelizumab).

More from news
Approximately 20 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Cortellis Drugs to Watch in 2020 report

To succeed, it will have to differentiate from its main direct competitor, the anti-CD20 monoclonal antibody Ocrevus, which has the first-to-market advantage, has labelled indications covering 95% of ... Even if bettering Ocrevus appears unlikely, the

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Surviving cancer: a new era for patients: Now more than ever, a shift in perspective is needed...
Crisis? No problem!: Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?: First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....